A new publication represents a possible small-molecule approach to potentially treat the synaptic dysfunction observed in Angelman syndrome.
Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model. Link to Article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185757/ We are excited to announce a new publication from Dr. John Marshall at Brown University made possible by FAST funding. The project started in late September 2022, aiming to modulate synaptic function with two novel […]